Literature DB >> 20051250

Co-stimulation with TLR7/8 and TLR9 agonists induce down-regulation of innate immune responses in sheep blood mononuclear and B cells.

Jayaum S Booth1, Joram J Buza, Andrew Potter, Lorne A Babiuk, George K Mutwiri.   

Abstract

Toll-like receptors (TLRs) play an important role in the activation of innate and adaptive immune responses. Stimulation with multiple TLR agonists may result in synergistic, complimentary or inhibitory effects on innate immune responses. In this study, we investigated the effects of co-stimulation of sheep peripheral blood mononuclear cells (PBMC) and B cells with agonists for TLR3, 4, 7/8 and 9. Sheep PBMC stimulated with either CpG (TLR9 agonist) or RNA oligoribonucleotides ([ORNs], TLR7/8 agonist) exhibited significant IL-12 production, but only CpG induced IFNalpha, IgM and proliferative responses. In contrast, poly(I:C) (TLR3 agonist) and LPS (TLR4 agonist) did not induce any of these responses. Interestingly, we observed that co-stimulation of PBMC with CpG+ORN or CpG+imiquimod (another TLR7/8 agonist) resulted in significant reduction in CpG-induced IFNalpha production, B cell proliferation and IgM responses. Pre-incubation of cells with CpG prior to exposure of the cells to imiquimod resulted in similar inhibitory responses indicating that the down-regulatory mechanisms are not associated with competition for cellular uptake or for receptors of the two agonists. Sheep B cells constitutively expressed TLR7, TLR8 and TLR9 mRNA transcripts, suggesting a possible role of TLR cross-talk in the down-regulatory mechanisms. Down-regulation of responses by co-stimulation with closely related TLRs may be a regulatory mechanism by which the host prevents overstimulation of innate immune responses. Copyright (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20051250     DOI: 10.1016/j.dci.2009.12.018

Source DB:  PubMed          Journal:  Dev Comp Immunol        ISSN: 0145-305X            Impact factor:   3.636


  5 in total

1.  Dual activation of Toll-like receptors 7 and 9 impairs the efficacy of antitumor vaccines in murine models of metastatic breast cancer.

Authors:  Mariela A Moreno Ayala; María Florencia Gottardo; María Soledad Gori; Alejandro Javier Nicola Candia; Carla Caruso; Andrea De Laurentiis; Mercedes Imsen; Slobodanka Klein; Elisa Bal de Kier Joffé; Gabriela Salamone; Maria G Castro; Adriana Seilicovich; Marianela Candolfi
Journal:  J Cancer Res Clin Oncol       Date:  2017-04-21       Impact factor: 4.553

2.  Assessment of the effect of TLR7/8, TLR9 agonists and CD40 ligand on the transformation efficiency of Epstein-Barr virus in human B lymphocytes by limiting dilution assay.

Authors:  Vahid Younesi; Forough Golsaz Shirazi; Ali Memarian; Amir Amanzadeh; Mahmood Jeddi-Tehrani; Fazel Shokri
Journal:  Cytotechnology       Date:  2013-02-13       Impact factor: 2.058

3.  Toll-like receptor responses to Peste des petits ruminants virus in goats and water buffalo.

Authors:  Sakthivel Dhanasekaran; Moanaro Biswas; Ambothi R Vignesh; R Ramya; Gopal Dhinakar Raj; Krishnaswamy G Tirumurugaan; Angamuthu Raja; Ranjit S Kataria; Satya Parida; Subbiah Elankumaran; Elankumaran Subbiah
Journal:  PLoS One       Date:  2014-11-04       Impact factor: 3.240

4.  Immunogenicity of a peptide-based anti-IgE conjugate vaccine in non-human primates.

Authors:  Risini D Weeratna; Ghania Chikh; Lu Zhang; James D Fraser; Jennifer M Thorn; James R Merson; Michael J McCluskie; Brian R Champion; Heather L Davis
Journal:  Immun Inflamm Dis       Date:  2016-04-01

5.  Anti-IgE Qb-VLP Conjugate Vaccine Self-Adjuvants through Activation of TLR7.

Authors:  Bassel Akache; Risini D Weeratna; Aparna Deora; Jennifer M Thorn; Brian Champion; James R Merson; Heather L Davis; Michael J McCluskie
Journal:  Vaccines (Basel)       Date:  2016-01-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.